Group 1 - The chairman and CEO of the company, Dr. Tong Youzhi, increased his stake in the company by purchasing 200,000 shares for HKD 259,000 at an average price of HKD 1.295 per share, representing approximately 0.0447% of the total issued share capital as of the announcement date [1] - Dr. Tong exercised rights to 1.25 million restricted stock units, corresponding to 1.25 million ordinary shares, which vested on March 31, 2025 [1] - Following this acquisition, Dr. Tong holds a total of 49.2003 million shares, representing about 10.99% of the total issued share capital as of the announcement date [1] Group 2 - The increase in shareholding demonstrates Dr. Tong's strong confidence in the company's commercialization prospects and growth potential, as well as recognition of its long-term investment value [2] - The company plans to continue focusing on the dermatology field, enhancing existing cosmetic products, broadening product coverage, and accelerating the launch of new cosmetic products to enrich its product matrix [2] - The company is actively exploring the market potential for effective raw materials, specifically KT-939 and KX-826, and is seeking collaboration opportunities with cosmetic brand owners to expand its raw material business and cultivate new profit growth points [2]

证券代码：600755 股票简称：厦门国贸 编号：2025-23 厦门国贸集团股份有限公司 关于控股股东以专项贷款和自有资金 增持公司股份计划的进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 基于对公司未来持续发展的坚定信心和对公司长期价值的认可，为增强投资者信心，提升公司价值，切 实维护广大投资者利益，国贸控股计划自本次增持计划公告披露之日起6个月内，通过上海证券交易所 集中竞价交易等方式增持公司股份，累计增持金额不低于20,264万元，不高于40,528万元。具体内容详 重要内容提示： ● 增持计划的基本情况：2024年10月31日，厦门国贸集团股份有限公司（以下简称"公司"）发布《厦门 国贸集团股份有限公司关于控股股东以专项贷款和自有资金增持公司股份计划的公告》，公司控股股东 厦门国贸控股集团有限公司（以下简称"国贸控股"）计划自本次增持计划公告披露之日起6个月内，通 过上海证券交易所集中竞价交易等方式增持公司股份，累计增持金额不低于20,264万元， ...

Core Viewpoint - Northeast Pharmaceutical (000597) announced that its controlling shareholder's concerted action party, Jiangxi Fangda Steel Group Co., Ltd., will increase its shareholding in the company by 1.5175 million shares from April 9 to April 15, 2025, representing 0.106% of the total share capital [1] Group 1 - After this increase, the controlling shareholder and its concerted action parties will hold a total of 786 million shares, accounting for 55.00% of the company's total share capital [1] - The share increase is supported by a special loan for stock repurchase and increase, amounting to RMB 108 million, with a loan term of 36 months and an interest rate of 2.25% [1]

钒钛股份（000629）公告，公司控股股东计划通过深圳证券交易所系统增持公司股份。本次增持计划的 实施期限为自公告之日起不超过6个月，增持金额不低于5000万元，不超过1亿元。控股股东表示，本次 增持主要是基于对公司未来发展前景的信心和对公司价值的认可，旨在进一步提升公司股东的信任度和 市场信心。公司提醒投资者关注相关风险，并注意投资决策。 ...

证券板块 政策层面形成"类平准基金机制+增持回购再贷款"工具组合拳，证券行业资本运作进入自我价值重估新阶段。上市 券商密集启动市场化回购：1）国泰海通发布公告称拟回购资金不低于人民币 10 亿元，不超过人民币 20 亿元；2）东 方证券公告筹划回购 2.5-5 亿元；3）国金证券拟回购资金总额不低于人民币 5,000 万元（含），不超过人民币 1 亿元 （含）；4）财通证券董事长提议回购股份金额为 1.5 亿元-3 亿元；5）中泰证券董事长提议回购资金为 3 亿元-5 亿元。 投资建议：多家公司发布业绩预增公告，在市场交投延续活跃以及低基数效应影响下，券商 25Q1 经纪、自营业务向 好驱动业绩表现同比大幅提升。券商和多元板块建议关注四条主线：（1）四川双马：科技赛道占优+退出渠道改善，业 绩弹性可期。公司管理基金的已投项目——奕斯伟（半导体材料，2024/12/24 状态更新为已问询）、邦德激光（高端 装备，2024/1/3 进行上市辅导备案）、屹唐半导体（2025/3/13 证监会批复注册）、群核科技（"杭州六小龙"之一， 2025/2/14 向港交所递交上市申请）、丽豪半导体（公司称拟最快 2025 年 ...

近一周（4月7日至4月12日，下同），深圳证券交易所（以下简称"深市"）上市公司、股东积极开展回 购、增持。数据显示，4月7日以来，深市累计213家公司披露回购增持公告。其中，回购计划73家，拟 回购金额181至328亿元；回购进展96家；增持计划24家，拟增持金额为66至94亿元；增持进展20家。 分行业来看，电子、机械设备、电子设备、汽车、计算机等行业公司较为集中。数据显示，近一周，申 万一级行业电子、机械设备、电力设备行业公司分别有22家、8家和7家公司推出回购增持计划，金额分 别为55亿元至85亿元、25亿元至46亿元、47亿元至93亿元。 例如，阳光电源4月9日披露回购方案，拟以3亿元至6亿元回购公司A股股份，用于实施公司股权激励或 员工持股计划。公司相关负责人表示，此次回购主要是对公司未来发展的信心和对公司价值的认可。 "回购+增持"双管齐下 值得注意的是，多家公司同时推出回购与增持计划，双管齐下向市场传递积极信号。 4月10日，浪潮信息发布公告称，公司董事长彭震提议回购公司部分股份，回购金额2亿元至3亿元，用 于减少公司注册资本等法律法规允许的用途。公司同时还表示，其控股股东计划自本公告披露之日 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司控股股东融捷投资控股集团有限公司保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、融捷股份有限公司（以下简称"公司"）控股股东融捷投资控股集团有限公司（以下简称"融捷集 团"）计划自本公司公告披露之日起的6个月内，以自有资金和股票增持专项贷款通过深圳证券交易所交 易系统允许的方式增持公司股份，增持金额不低于人民币6,000万元，不超过人民币12,000万元。 2、本次增持计划可能存在因资本市场情况发生变化、增持资金未能及时筹措到位等因素导致增持计划 延迟实施或者无法完成实施的风险。增持计划实施过程中如出现上述风险情形，公司将及时履行信息披 露义务。敬请广大投资者注意相关风险。 近日，公司收到融捷集团《关于计划增持融捷股份有限公司股份的告知函》，现将相关内容公告如下： 一、计划增持主体的基本情况 1、增持主体为融捷集团，融捷集团直接持有公司股份61,857,992股，占公司总股本的23.82%，融捷集 团及其一致行动人合计持有公司股份65, ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 ●本次权益变动属于增持，不触及要约收购。 登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 南京银行股份有限公司关于部分股东增持股份的公告 特别提示： 注：本公司可转债"南银转债"已于2021年12月21日进入转股期，截至2025年4月10日本公司总股本为 11,075,041,994股。 截至2025年4月10日，紫金集团及其控股子公司紫金信托合计持有本公司股份比例为13.73%；东部机场 集团投资有限公司持有本公司股份比例为2.60%。 二、其他情况说明 ●南京紫金投资集团有限责任公司控股子公司紫金信托有限责任公司于2024年10月8日至2025年4月10日 期间，合计增持本公司股份77,130,523股，占本公司总股本比例为0.70%；东部机场集团投资有限公司 于2024年10月10日至2025年4月10日期间，合计增持本公司股份172,722,924股，占本公司总股本比例为 1.56%。 本公司总股本以2025年4月10日总股本11,075,041,99 ...

Core Viewpoint - Since 2025, A-share listed banks have seen significant increases in shareholding by executives and major shareholders, particularly accelerating since April 2023, driven by policy guidance, market confidence, and valuation recovery needs [1][4]. Group 1: Recent Actions and Announcements - On April 9, Huaxia Bank announced that its directors, supervisors, and senior management plan to voluntarily increase their shareholding by at least 30 million yuan within six months starting from April 11, 2025 [2]. - Jiangsu Bank also reported that its senior management and some directors plan to increase their A-share holdings by at least 20 million yuan through concentrated bidding [2]. - Postal Savings Bank and Chengdu Bank disclosed their major shareholders' ongoing shareholding increases, with Postal Savings Bank's major shareholder increasing 19.91 million shares, representing 0.02% of its total issued shares [2]. Group 2: Market Impact and Analyst Insights - The recent surge in shareholding among A-share listed banks reflects confidence from both local state-owned platforms and internal management teams regarding the banks' fundamentals [3]. - Analysts predict that this trend will boost market sentiment, attract long-term investors to the banking sector, and enhance governance structures by aligning management interests with shareholder returns [3][4]. - The scale of shareholder increases is expected to grow, particularly among state-owned banks due to their strong capital positions and lower valuations, while regional banks may also participate if supported by shareholders [4].

Core Viewpoint - Qingdao Haier Biomedical Co., Ltd. announced that its actual controller's concerted action party, Haichuangzhi, has completed a share buyback plan, acquiring 5,729,305 shares, which is 1.8% of the total share capital, for a total amount of 181.84 million yuan [2][8]. Group 1 - The share buyback plan was initiated on January 8, 2025, with a target to purchase between 100 million yuan and 200 million yuan within six months [2][6]. - As of April 10, 2025, Haichuangzhi has completed the buyback, with an average purchase price of 31.74 yuan per share [7][8]. - Following the buyback, Haichuangzhi holds 8,675,900 shares, representing 2.73% of the total share capital, while Haier Group and its concerted action parties collectively hold 141,371,022 shares, or 44.46% of the total [8]. Group 2 - The purpose of the buyback is to enhance investor confidence based on the belief in the company's future development and long-term investment value [4]. - The buyback was executed through a centralized bidding method on the Shanghai Stock Exchange [7]. - The buyback plan did not set a price range and was subject to market conditions [7].